Burixafor (hydrobromide)

Burixafor (TG-0054) hydrobromide is a selective, orally active CXCR4 antagonist that effectively blocks the interaction between CXCR4 and its ligand, stromal cell-derived factor SDF-1. Burixafor hydrobromide interferes with the SDF-1/CXCR4 signaling pathway, prompting the release of bone marrow stem cells into the peripheral circulation, exerting immunomodulatory and anti-inflammatory activities. Burixafor hydrobromide can be used in the study of cancer, Intraocular neovascular diseases (such as choroidal neovascularization), myocardial infarction and other diseases, with the potential to mobilize stem cells, improve cardiac function and reduce inflammatory responses[1][2][3].

Product Specifications

CAS Number

[1191450-19-7]

Product Name Alternative

TG-0054 (hydrobromide)

UNSPSC

12352005

Target

CXCR; VEGFR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Endocrinology; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Burixafor_hydrobromide.html

Purity

98.0

Solubility

H2O : 50 mg/mL (ultrasonic)

Smiles

NC1=CC(N2CCN(CCP(O)(O)=O)CC2)=NC(NC[C@H]3CC[C@H](CNCCCNC4CCCCC4)CC3)=N1.[H]Br

Molecular Formula

C27H51N8O3P.5/2HBr

Molecular Weight

769.01

References & Citations

[1]Nuñez RE, et al. Microglial Cytokines Induce Invasiveness and Proliferation of Human Glioblastoma through Pyk2 and FAK Activation. Cancers (Basel) . 2021 Dec 7;13 (24) :6160.|[2]Hsu WT, et al. CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction. Cell Transplant. 2015;24 (7) :1313-28.|[3]Shelke NB, et al. Intravitreal Poly (L-lactide) Microparticles Sustain Retinal and Choroidal Delivery of TG-0054, a Hydrophilic Drug Intended for Neovascular Diseases. Drug Deliv Transl Res. 2011 Feb;1 (1) :76-90.